Integrated cancer pharmacogenomics: identification of therapeutic vulnerabilities from multiple-dimensional cancer genomic data

Seminar Date: 
Seminar Time: 
11am - 12pm
Seminar Location: 
5607 Baum Boulevard, Room 407A
Da Yang, PhD


Cancer is a highly heterogeneous disease even for the ones originated from the same organ. To identify potential clinically actionable therapeutic targets that may inform individualized treatment strategies, we have made use of large scale cancer genomics profiling of tumor samples in The Cancer Genome Atlas to systematically search for tumor vulnerabilities. The approach have proved successful in several instances especially in ovarian cancer, including the identification of miR-506 as a tumor suppressor miRNA inhibiting tumor metastasis by targeting Epithelial-to-Mesenchymal (EMT) and the discovery of BRCA2 gene mutations leading to the genome instability and cisplatin response in ovarian cancer.